The introduction of the prostate-specific antigen (PSA) blood test has increased detection of prostate cancer in the US, and most men are now diagnosed with localized, early stage and low-risk tumors (PSA < 10 ng/mL, clinical staging T1-T2a, and Gleason score ≤6) [1–3]. This evidence concerns the gene KLK3 and prostate carcinoma.